Raphael Pharmaceutical Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
CONSOLIDATED STATEMENTS OF CHANGES STOCKHOLDERS’ IN EQUITY (DEFICIT)
| Common stock · Additional paid-in · Accumulated · Total | |||||
|---|---|---|---|---|---|
| Number | Amount | capital | deficit | equity | |
| Balance as of January 1, 2022 | 12,970,540 | $130 | $2,666 | $(2,668) | $128 |
| Issuance of common stock and warrants | 831,000 | 8 | 885 | - | 893 |
| Issuance of common stock in exchange for services | 1,822,500 | 19 | 2,424 | - | 2,443 |
| Net loss | - | - | - | (3,358) | (3,358) |
| Balance as of December 31, 2022 | 15,624,040 | $157 | $5,975 | $(6,026) | $106 |
| Common stock · Additional paid-in · Accumulated · Total | |||||
|---|---|---|---|---|---|
| Number | Amount | capital | deficit | equity | |
| Balance as of January 1, 2023 | 15,624,040 | $157 | $5,975 | $(6,026) | $106 |
| Issuance of common stock and warrants | 2,677,878 | 26 | 1,219 | - | 1,245 |
| Issuance of common stock in exchange for services | 201,000 | 2 | 198 | - | 200 |
| Net loss | - | - | - | (1,284) | (1,284) |
| Balance as of December 31, 2023 | 18,502,918 | 185 | $7,392 | $(7,310) | $(267) |
The accompanying notes are an integral part of the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.